Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01557088 · ClinicalTrials.gov registry record · NA
Lp-PLA2 and Coronary Atherosclerosis in Humans
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 166
- Enrollment target
NCT01557088: Completed NA study, sponsored by Mayo Clinic.
NCT01557088 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 166 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01557088, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 166 participants
- Enrollment target
Study Summary
The majority of the acute coronary events are caused by coronary artery segments with minimal luminal disease, but with potentially significant vascular wall inflammation and oxidative stress leading to plaque vulnerability. It has become apparent that an initial injury at the endothelial surface, is the primary site of the mechanisms involved and a role for vascular inflammation and the interaction with oxidative stress continues to emerge. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a novel biomarker for vascular wall inflammation that circulates in the blood bound to both low density (LDL) and high density (HDL) lipoprotein and promotes vascular inflammation. Circulating levels of Lp-PLA2 mass and activity are an independent risk factor for cardiovascular events. Recent studies, demonstrating that Lp-PLA2 is also associated with coronary endothelial dysfunction. However, the relationship between Lp-PLA2 and early atherosclerotic changes in the coronary arteries, and the contribution of lipoprotein binding to the deleterious potential of Lp- PLA2 have not been elucidated. Our working hypothesis is that the endogenous local activation of the Lp-PLA2 pathway plays an integral role in early coronary atherosclerosis and contributes to the mechanism of coronary endothelial dysfunction and the structural and mechanical properties reflecting plaque vulnerability. Thus, the current application will characterize prospectively the correlation between the functional, mechanical, and structural vascular wall properties, and the systemic as well as the coronary activity of the Lp-PLA2 pathway.
Primary Outcome
AIM 1: To assess the relationship between the 3 inflammatory measures of the Lp-PLA2 pathway (Lp-PLA2 mass, Lp-PLA2 activity and LysoPC) with endothelial function (as measured by the percent change in CAD (coronary artery disease) \[Ach\] and by the length of segments with endothelial dysfunction and plaque vulnerability (as measured by the necrotic core percent volume). AIM II: To assess the association between the percent of Lp-PLA2 residing on LDL and endothelial function (again measured by p
Interventions
- OTHER Blood sampling from the Coronary Sinus and Aorta
- PROCEDURE Intravascular Ultrasound of the coronary artery.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-06 |
| Phase | NA |
What the finished NCT01557088 record still lists
NCT01557088 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Blood sampling from the Coronary Sinus and Aorta is the first listed.
NCT01557088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01557088 about?
NCT01557088 is a clinical study titled "Lp-PLA2 and Coronary Atherosclerosis in Humans". The majority of the acute coronary events are caused by coronary artery segments with minimal luminal disease, but with potentially significant vascular wall inflammation and oxidative stress leading to plaque vulnerability. It has become apparent that an initial injury at the endothelial surface, i...
What is the current status of trial NCT01557088?
This trial is currently completed. It is a NA study. The enrollment target is 166 participants. The study started on 2009-02. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01557088?
The interventions under investigation include: Blood sampling from the Coronary Sinus and Aorta (OTHER), Intravascular Ultrasound of the coronary artery. (PROCEDURE).
Who is sponsoring clinical trial NCT01557088?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01557088's enrollment target sits among peer trials
166 625th of 2000 higher than 1,375 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia